Literature DB >> 12589871

A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS.

Johan Marinus1, Martine Visser, Pablo Martínez-Martín, Jacobus J van Hilten, Anne M Stiggelbout.   

Abstract

The purpose of this study was to develop a short questionnaire for psychosocial functioning in patients with Parkinson's Disease (PD). The SCales for Outcomes in Parkinson's disease-PsychoSocial questionnaire (SCOPA-PS) was tested in a survey and compared with other instruments and with medical information. This survey was sent to 205 patents with idiopathic PD. Eighty-six percent of the questionnaires were returned. Cronbach's alpha was 0.83. Two-week test-retest reliability was 0.85 (intraclass correlation coefficient). Construct validity with other scales (Spearman's rho) was 0.82 for the Parkinson's Disease Questionnaire-39-item version (PDQ-39), 0.76 for the PDQ-8, 0.69 for the Hospital Anxiety and Depression Scale, -0.61 for the Euroqol, and -0.60 for a visual analogue scale evaluating Quality-of-Life. The summary index revealed a significant increase with increasing disease severity. The SCOPA-PS is a new, short psychosocial questionnaire for patients with PD with good clinimetric properties.

Entities:  

Mesh:

Year:  2003        PMID: 12589871     DOI: 10.1016/s0895-4356(02)00569-3

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  22 in total

1.  Health-related quality of life as an outcome variable in Parkinson's disease.

Authors:  Pablo Martinez-Martin; Mónica M Kurtis
Journal:  Ther Adv Neurol Disord       Date:  2012-03       Impact factor: 6.570

Review 2.  Management of Parkinson's disease dementia : practical considerations.

Authors:  Arvid Rongve; Dag Aarsland
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  What Should Constitute a Health Related Quality of Life Scale for Parkinson's Disease?

Authors:  Rajeev Aggarwal; Vinay Goyal; Ravindra Mohan Pandey; Nand Kumar; Sumit Singh; Garima Shukla; Madhuri Behari
Journal:  J Clin Diagn Res       Date:  2016-09-01

4.  The impact of subthalamic deep brain stimulation on caregivers of Parkinson's disease patients: an exploratory study.

Authors:  Catharine J Lewis; Franziska Maier; Nina Horstkötter; Carsten Eggers; Veerle Visser-Vandewalle; Elena Moro; Mateusz Zurowski; Jens Kuhn; Christiane Woopen; Lars Timmermann
Journal:  J Neurol       Date:  2014-11-09       Impact factor: 4.849

5.  Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.

Authors:  Maria Jose Catalan; Jose Antonio Molina-Arjona; Pablo Mir; Esther Cubo; Jose Matias Arbelo; Pablo Martinez-Martin
Journal:  J Neurol       Date:  2018-03-20       Impact factor: 4.849

6.  A comprehensive model of health-related quality of life in Parkinson's disease.

Authors:  M Visser; S M van Rooden; D Verbaan; J Marinus; A M Stiggelbout; J J van Hilten
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

Review 7.  Instruments for holistic assessment of Parkinson's disease.

Authors:  Pablo Martinez-Martin
Journal:  J Neural Transm (Vienna)       Date:  2013-03-10       Impact factor: 3.575

8.  Co-occurring chronic conditions and healthcare expenditures associated with Parkinson's disease: a propensity score matched analysis.

Authors:  Sandipan Bhattacharjee; Usha Sambamoorthi
Journal:  Parkinsonism Relat Disord       Date:  2013-05-13       Impact factor: 4.891

9.  Development, reliability and validity of the psychosocial adaptation scale for Parkinson's disease in Chinese population.

Authors:  Tingting Zhang; Anchun Yin; Xiaohong Sun; Qigui Liu; Guirong Song; Lianhong Li
Journal:  Int J Clin Exp Med       Date:  2015-10-15

10.  Quality of life in Parkinson's disease: Italian validation of the Parkinson's Disease Questionnaire (PDQ-39-IT).

Authors:  Giovanni Galeoto; Francesca Colalelli; Perla Massai; Anna Berardi; Marco Tofani; Mariangela Pierantozzi; Annamaria Servadio; Andrea Fabbrini; Giovanni Fabbrini
Journal:  Neurol Sci       Date:  2018-08-07       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.